<Record><identifier xmlns="http://purl.org/dc/elements/1.1/">URN:NBN:SI:doc-I0LD5WS5</identifier><date>2008</date><creator>Bošković, Marija</creator><creator>Vovk, Tomaž</creator><relation>documents/znanstveni_clanki/farmacevtski_vestnik/html/urn_nbn_si_doc-i0ld5ws5.html</relation><relation>documents/znanstveni_clanki/farmacevtski_vestnik/pdf/urn_nbn_si_doc-i0ld5ws5.pdf</relation><relation>documents/znanstveni_clanki/farmacevtski_vestnik/txt/urn_nbn_si_doc-i0ld5ws5.txt</relation><format format_type="issue">4</format><format format_type="volume">59</format><format format_type="main">7 strani</format><format format_type="type">article</format><format format_type="extent">str. 167-173</format><identifier identifier_type="ISSN">0014-8229</identifier><identifier identifier_type="COBISSID">2417009</identifier><identifier identifier_type="URN">URN:NBN:SI:doc-I0LD5WS5</identifier><language>eng</language><publisher>Slovensko farmacevtsko društvo</publisher><source>Farmacevtski vestnik</source><rights>InC</rights><subject language_type_id="slv">maščobne kisline</subject><subject language_type_id="slv">oksidativni stres</subject><subject language_type_id="slv">shizofrenija</subject><subject language_type_id="slv">vitamin C</subject><subject language_type_id="eng">vitamin E</subject><title>Can supplementation with vitamin E or C and omega-3 or -6 fatty acids improve the outcome of schizophrenia?</title></Record>